Additive Positive Inotropic Effects of Milrinone, Ouabain and Calcium in Diseased Human Ventricular Myocardium

Overview

Journal Klin Wochenschr

Specialty General Medicine

Date 1986 Aug 1

PMID 3762018

Citations 1

Authors

L Brown

M Nabauer

E Erdmann

Affiliations

Soon will be listed here.

Abstract

The interactions of milrinone, ouabain and calcium on force of contraction in isolated, contracting human papillary muscle strips were measured. Milrinone (EC50, 8 X 10(-5)M) increased force of contraction maximally by 2.8 +/- 0.8 mN at 5 X 10(-4)M; significantly less than either ouabain (1 X 10(-7)M; 4.8 +/- 0.5 mN increase) or calcium (15 mM; 6.2 +/- 0.6 mN increase). A submaximal, but not a maximal, inotropic effect of ouabain could be increased by the addition of milrinone; in contrast, both ouabain and calcium increased the maximal inotropic effect of milrinone by 1.7 +/- 0.2 mN and 2.7 +/- 0.3 mN, respectively. The combined inotropic effect of milrinone with either ouabain of 4.2 +/- 0.3 mN or calcium of 5.6 +/- 0.4 mN was not different from that with calcium or ouabain alone. We conclude that further positive inotropic effects should be expected when digitalis is given to patients with congestive heart failure who are already optimally treated with milrinone.

Citing Articles

The effectiveness of inotropic agents in isolated cardiac preparations from the human heart.

Erdmann E Klin Wochenschr. 1988; 66(1):1-6.

PMID: 2449564 DOI: 10.1007/BF01735205.

References

Bristow M, Ginsburg R, Minobe W, Cubicciotti R, Sageman W, Lurie K . Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982; 307(4):205-11. DOI: 10.1056/NEJM198207223070401. View

Baim D, MCDOWELL A, Cherniles J, Monrad E, Parker J, Edelson J . Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure. N Engl J Med. 1983; 309(13):748-56. DOI: 10.1056/NEJM198309293091302. View

Siegl P, MORGAN G, Sweet C . Responses to amrinone in isolated cardiac muscles from cat, rabbit, and guinea pig. J Cardiovasc Pharmacol. 1984; 6(2):281-7. DOI: 10.1097/00005344-198403000-00012. View

Wilmshurst P, Walker J, Fry C, MOUNSEY J, Twort C, Williams B . Inotropic and vasodilator effects of amrinone on isolated human tissue. Cardiovasc Res. 1984; 18(5):302-9. DOI: 10.1093/cvr/18.5.302. View

Tse J, Powell J, Baste C, PRIEST R, Kuo J . Isoproterenol-induced cardiac hypertrophy: modifications in characteristics of beta-adrenergic receptor, adenylate cyclase, and ventricular contraction. Endocrinology. 1979; 105(1):246-55. DOI: 10.1210/endo-105-1-246. View

Jaski B, Fifer M, Wright R, Braunwald E, Colucci W . Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest. 1985; 75(2):643-9. PMC: 423546. DOI: 10.1172/JCI111742. View

Saragoca M, TARAZI R . Impaired cardiac contractile response to isoproterenol in the spontaneously hypertensive rat. Hypertension. 1981; 3(3):380-5. DOI: 10.1161/01.hyp.3.3.380. View

Bendersky R, Chatterjee K, Parmley W, Brundage B, Ports T . Dobutamine in chronic ischemic heart failure: alterations in left ventricular function and coronary hemodynamics. Am J Cardiol. 1981; 48(3):554-8. DOI: 10.1016/0002-9149(81)90087-4. View

Ginsburg R, Bristow M, Billingham M, Stinson E, Schroeder J, Harrison D . Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J. 1983; 106(3):535-40. DOI: 10.1016/0002-8703(83)90698-1. View

10.

Will-Shahab L, Krause E, Bartel S, Schulze W, Kuttner I . Reversible inhibition of adenylate cyclase activity in the ischemic myocardium. J Cardiovasc Pharmacol. 1985; 7 Suppl 5:S23-7. DOI: 10.1097/00005344-198500075-00006. View

11.

Brown L, Lorenz B, Erdmann E . The inotropic effects of dopamine and its precursor levodopa on isolated human ventricular myocardium. Klin Wochenschr. 1985; 63(21):1117-23. DOI: 10.1007/BF02291093. View

12.

Honerjager P, Schafer-Korting M, Reiter M . Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence. Naunyn Schmiedebergs Arch Pharmacol. 1981; 318(2):112-20. DOI: 10.1007/BF00508835. View

13.

Klein N, Siskind S, Frishman W, SONNENBLICK E, Lejemtel T . Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure. Am J Cardiol. 1981; 48(1):170-5. DOI: 10.1016/0002-9149(81)90587-7. View

14.

Fouad F, Shimamatsu K, Hanna M, Khairallah P, TARAZI R . Impaired inotropic responses to alpha-adrenergic stimulation in experimental left ventricular hypertrophy. Circulation. 1985; 71(5):1023-8. DOI: 10.1161/01.cir.71.5.1023. View

15.

Monrad E, Baim D, Smith H, Lanoue A, Brauwald E, Grossman W . Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation. 1985; 71(5):972-9. DOI: 10.1161/01.cir.71.5.972. View

16.

ALOUSI A, Stankus G, Stuart J, Walton L . Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J Cardiovasc Pharmacol. 1983; 5(5):804-11. DOI: 10.1097/00005344-198309000-00015. View

17.

Brown L, Erdmann E . Concentration-response curves of positive inotropic agents before and after ouabain pretreatment. Cardiovasc Res. 1985; 19(5):288-98. DOI: 10.1093/cvr/19.5.288. View

18.

Sinoway L, Maskin C, Chadwick B, Forman R, SONNENBLICK E, Le Jemtel T . Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol. 1983; 2(2):327-31. DOI: 10.1016/s0735-1097(83)80170-3. View

19.

Borow K, Come P, Neumann A, Baim D, Braunwald E, Grossman W . Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease. Am J Cardiol. 1985; 55(9):1204-9. DOI: 10.1016/0002-9149(85)90664-2. View

20.

Bristol J, Sircar I, Moos W, Evans D, Weishaar R . Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. J Med Chem. 1984; 27(9):1099-101. DOI: 10.1021/jm00375a001. View